Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma

NCT00422786 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Renal Cell

Interventions

DRUG: CAP-232

Sponsor

Thallion Pharmaceuticals